

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic NSCLC), and that has a certain type of abnormal "BRAF V600E" gene.

TAFINLAR, in combination with MEKINIST, is not for use in treating people with wild-type BRAF NSCLC.

Your health care provider will perform a test to make sure that TAFINLAR and MEKINIST in combination is right for you.

It is not known if TAFINLAR, in combination with MEKINIST, is safe and effective in children younger than 1 year of age. It is not known if TAFINLAR used alone is safe and effective in children.

This is my BRAF V600E metastatic NSCLC treatment plan.





IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TAFINLAR in combination with MEKINIST? TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new skin cancers.

TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers.

Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.

TAFINLAR + MEKINIST is a treatment option for your type of lung cancer called metastatic NSCLC that has a certain type of abnormal "BRAF V600E" gene.

It is normal to feel overwhelmed when processing all the medical information given to you by your health care provider after diagnosis of lung cancer called metastatic NSCLC that has a certain type of abnormal "BRAF V600E" gene. This brochure is meant to help you and those close to you understand your treatment with TAFINLAR + MEKINIST combination therapy. This information does not take the place of talking to your doctor about your condition or treatment.

Table of Contents

Understanding the genetic mutation differences of NSCLC	4
Your gene mutation status can help in choosing appropriate treatment	6
An FDA-approved treatment option specifically for BRAF V600E metastatic NSCLC	7
How TAFINLAR + MEKINIST may help BRAF V600E metastatic NSCLC	8
Summary of Important Information	10
How should I take TAFINLAR + MEKINIST?	14
Storing TAFINLAR and MEKINIST	16
Getting the most out of your treatment	18
Questions to ask your health care provider	19
Common side effects of TAFINLAR + MEKINIST	20
How your health care provider may help you manage your fever	21
Frequently asked questions	22
How can I learn more about NSCLC?	24
Support designed for patients and caregivers	26

IMPORTANT SAFETY INFORMATION (continued)

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Your health care provider should also check for cancers that may not occur on the skin. Tell your health care provider about any new symptoms that have developed while taking TAFINLAR and MEKINIST in combination.

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.






Understanding the genetic mutation differences of NSCLC

IMPORTANT SAFETY INFORMATION (continued)

Bleeding problems. TAFINLAR and MEKINIST in combination can cause serious bleeding problems, especially in your brain or stomach, that can lead to death. Call your health care provider and get medical help right away if you have any signs of bleeding, including:

- headaches, dizziness, or feeling weak
- coughing up blood or blood clots
- vomiting blood or your vomit looks like "coffee grounds"
- red or black stools that look like tar

Types of NSCLC Gene Mutations



Advances in genetic research have revealed that non-small cell lung cancer (NSCLC) is not a single disease, but rather many types of cancer with specific genetic differences that can cause cancer cells to grow and multiply.

The type of NSCLC can be based on the presence or absence of certain genetic changes within the lung cells. These genetic changes are called "gene mutations." Gene mutations can then contribute to the growth of tumors. Approximately 2% of patients with metastatic (cancer that has spread to other parts of the body) NSCLC have an abnormal *BRAF* gene mutation (V600E), which drives cancer cells to grow and spread out of control.

IMPORTANT SAFETY INFORMATION (continued)

Inflammation of the intestines or tears (perforation) of the stomach or intestines. MEKINIST, alone or in combination with TAFINLAR, can cause inflammation of your intestines, or tears in the stomach or intestines that can lead to death. Tell your health care provider right away if you have any of the following symptoms:

- bleeding (see "Bleeding problems")
- \bullet diarrhea (loose stools) or more bowel movements than usual
- stomach-area (abdomen) pain or tenderness

- fever
- nausea

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.





Your gene mutation status can help in choosing appropriate treatment

Lung cancer medicines that target the specific differences in gene mutations have been developed. For example, you or your loved one was tested with a biopsy (or tissue sample) of the cells to see if it contained a BRAF V600E mutation, which may be helpful when selecting a treatment.

When health care providers get the test results and know for sure that the NSCLC tumor has an abnormal BRAF gene, they specifically call it BRAF V600E NSCLC.



Knowing your gene mutation status can be crucial when you and your health care provider are choosing an appropriate treatment.

IMPORTANT SAFETY INFORMATION (continued)

Blood clots. TAFINLAR and MEKINIST in combination can cause blood clots in your arms or legs, which can travel to your lungs and lead to death. Get medical help right away if you have the following symptoms:

- chest pain
- sudden shortness of breath or trouble breathing
- pain in your legs with or without swelling
- swelling in your arms or legs
- a cool, pale arm or leg

IMPORTANT SAFETY INFORMATION (continued)

Heart problems, including heart failure. Your health care provider should check your heart function before you start taking TAFINLAR and MEKINIST in combination, and during treatment. Call your health care provider right away if you have any of the following signs and symptoms of a heart problem:

- feeling like your heart is pounding, racing, or beating irregularly
- shortness of breath
- swelling of your ankles and feet
- feeling lightheaded

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.

Please see accompanying full Prescribing Information for TAFINLAR, including Medication Guide, and full Prescribing Information for MEKINIST, including Patient Information.





A proven choice for patients with **BRAF V600E metastatic NSCLC**

If you have the BRAF V600E mutation, TAFINLAR + MEKINIST is a targeted therapy for your specific type of metastatic NSCLC.

How may TAFINLAR and MEKINIST be used to treat NSCLC?

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic NSCLC), and that has a certain type of abnormal "BRAF V600E" gene.

TAFINLAR, in combination with MEKINIST, is not for use in treating people with wild-type BRAF NSCLC.


Your health care provider will perform a test to make sure that TAFINLAR and MEKINIST in combination is right for you.

It is not known if TAFINLAR, in combination with MEKINIST, is safe and effective in children younger than 6 years of age.

How TAFINLAR + MEKINIST may help BRAF V600E metastatic NSCLC


In a clinical trial, TAFINLAR + MEKINIST was shown to help shrink or slow the growth of tumors in untreated and previously treated patients. The overall response rate measures the size or number of tumors. This number includes patients whose tumors became smaller or fewer in number (which is called a partial response), and patients whose tumors disappeared completely (which is called a complete response). Complete response is not the same as a cure.

OVERALL RESPONSE RATE



Untreated

A total of 61% of 36 untreated patients achieved a response with TAFINLAR + MEKINIST. A total of 8% of untreated patients had a complete response and 53% had a partial response.



Previously Treated

A total of 61% of 57 previously treated patients achieved a response with TAFINLAR + MEKINIST.

Of these responders, 5% had a complete response and 56% of patients had a partial response.

IMPORTANT SAFETY INFORMATION (continued)

Eye problems. TAFINLAR and MEKINIST, in combination, can cause severe eye problems that can lead to blindness. Call your health care provider right away if you get these symptoms of eye problems:

- blurred vision, loss of vision, or other vision changes
- seeing color dots
- halo (seeing blurred outline around objects)
- eye pain, swelling, or redness

Duration of Response

Duration of response is a measure of how long a treatment can keep tumors from growing again after a response has first been detected.



The median duration of response in untreated patients was 15.2 months.

The median (or midpoint) duration of response for patients who have never been treated was 15.2 months. This means that half of the patients who responded to treatment continued to respond longer than 15.2 months and half responded for less than 15.2 months.



The median duration of response to treatment was 9 months in previously treated patients.

The median (or midpoint) duration of response for patients who were previously treated was 9 months. This means that half of the patients who responded to treatment continued to respond longer than 9 months and half responded for less than 9 months.

IMPORTANT SAFETY INFORMATION (continued)

Lung or breathing problems. TAFINLAR and MEKINIST, in combination, can cause lung or breathing problems. Tell your health care provider if you have any new or worsening symptoms of lung or breathing problems, including:

- shortness of breath
- cough

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.

Tafinlar (dabrafenib) 50 mg, 75 mg capsules



Summary of Important Information

Approved Use

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic NSCLC), and that has a certain type of abnormal "BRAF V600E" gene.

TAFINLAR, in combination with MEKINIST, is not for use in treating people with wild-type *BRAF* NSCLC. Your health care provider will perform a test to make sure that TAFINLAR and MEKINIST in combination is right for you.

It is not known if TAFINLAR, in combination with MEKINIST, is safe and effective in children younger than 1 year of age. It is not known if TAFINLAR used alone is safe and effective in children.

Important Safety Information

What is the most important information I should know about TAFINLAR in combination with MEKINIST? TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new skin cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers.

Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Your health care provider should also check for cancers that may not occur on the skin. Tell your health care provider about any new symptoms that have developed while taking TAFINLAR and MEKINIST in combination.

Bleeding problems. TAFINLAR and MEKINIST in combination can cause serious bleeding problems, especially in your brain or stomach, that can lead to death. Call your health care provider and get medical help right away if you have any signs of bleeding, including:

- headaches, dizziness, or feeling weak
- coughing up blood or blood clots
- vomiting blood or your vomit looks like "coffee grounds"
- red or black stools that look like tar

Inflammation of the intestines or tears (perforation) of the stomach or intestines.

MEKINIST, alone or in combination with TAFINLAR, can cause inflammation of your intestines, or tears in the stomach or intestines that can lead to death. Tell your health care provider right away if you have any of the following symptoms:

- bleeding (see "Bleeding problems")
- diarrhea (loose stools) or more bowel movements than usual
- stomach-area (abdomen) pain or tenderness
- fever
- nausea

Blood clots. TAFINLAR and MEKINIST in combination can cause blood clots in your arms or legs, which can travel to your lungs and lead to death.

Get medical help right away if you have the following symptoms:

- chest pain
- sudden shortness of breath or trouble breathing
- pain in your legs with or without swelling
- swelling in your arms or legs
- a cool, pale arm or leg

Heart problems, including heart failure. Your health care provider should check your heart function before you start taking TAFINLAR and MEKINIST in combination, and during treatment. Call your health care provider right away if you have any of the following signs and symptoms of a heart problem:

- feeling like your heart is pounding, racing, or beating irregularly
- shortness of breath
- swelling of your ankles and feet
- feeling lightheaded

Eye problems. TAFINLAR and MEKINIST, in combination, can cause severe eye problems that can lead to blindness. Call your health care provider right away if you get these symptoms of eye problems:

- blurred vision, loss of vision, or other vision changes
- seeing color dots
- halo (seeing blurred outline around objects)
- eye pain, swelling, or redness

Lung or breathing problems. TAFINLAR and MEKINIST, in combination, can cause lung or breathing problems. Tell your health care provider if you have any new or worsening symptoms of lung or breathing problems, including:

- shortness of breath
- cough

Fever. Fever is common during treatment with TAFINLAR and MEKINIST, but it may also be serious. When taking TAFINLAR and MEKINIST, in combination, fever may happen often or may be severe. In some cases, chills or shaking chills, too much fluid loss (dehydration), low blood pressure, dizziness, or kidney problems may happen with the fever. Call your health care provider right away if you get a fever while taking TAFINLAR or MEKINIST. Your health care provider may temporarily or permanently stop your treatment or change your dose of MEKINIST with TAFINLAR if you have fevers. Your health care provider will treat you as needed for

your fever and any signs and symptoms of infection

and should check your kidney function during and

Serious skin reactions. Skin rash is a common side effect of TAFINLAR and MEKINIST. In some cases, these rashes and other skin reactions can be severe or serious, may need to be treated in a hospital, or lead to death.

- tell your health care provider if you get a skin rash or acne that bothers you or worsens
- tell your health care provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including:
- o blisters or peeling of your skin

after you have had severe fever.

- mouth sores
- high fever or flu-like symptoms
- blisters on your lips, or around your mouth or eyes
- enlarged lymph nodes





Summary of Important Information (continued)

Increased blood sugar (hyperglycemia). Some people may develop high blood sugar or worsening diabetes during treatment with TAFINLAR and MEKINIST in combination. If you are diabetic, your health care provider should check your blood sugar levels closely during treatment with TAFINLAR and MEKINIST. Your diabetes medicine may need to be changed. Tell your health care provider if you have any of the following symptoms of severe high blood sugar:

- increased thirst
- urinating more often than normal, or urinating an increased amount of urine

TAFINLAR may cause healthy red blood cells to break down too early in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This may lead to a type of anemia called hemolytic anemia, where the body does not have enough healthy red blood cells. Tell your health care provider if you have any of the following signs or symptoms:

- yellow skin (jaundice)
- weakness or dizziness
- shortness of breath

Hemophagocytic Lymphohistiocytosis (HLH).

TAFINLAR when taken with MEKINIST may increase the risk of a type of overactivity of the immune system (hemophagocytic lymphohistiocytosis) that can cause fever, swollen glands, bruising, or skin rash. If you experience a combination of these symptoms, call your health care provider right away.

TAFINLAR and MEKINIST, in combination, can harm your unborn baby.

Your health care provider will do a test to see if you are pregnant before starting treatment with TAFINLAR and MEKINIST in combination.

Women who are able to become pregnant should use effective birth control (contraception)

during treatment with TAFINLAR and MEKINIST in combination, and for 4 months after stopping treatment with TAFINLAR and MEKINIST.

Birth control using hormones (such as birth control pills, injections, or transdermal systems) may not work as well while you are taking TAFINLAR and MEKINIST in combination. You should use another effective method of birth control while taking TAFINLAR and MEKINIST in combination.

Talk to your health care provider about birth control methods that may be right for you during this time. Tell your health care provider right away if you become pregnant, or think you might be pregnant, during treatment with TAFINLAR and MEKINIST in combination.

Men (including those who have had a vasectomy) with a female partner who is able to become pregnant should use condoms during sexual intercourse during treatment with TAFINLAR and MEKINIST for at least 4 months after your last dose of TAFINLAR and MEKINIST in combination.

The most common side effects of TAFINLAR, in combination with MEKINIST, when used in people with NSCLC, include:

- fever
- tiredness
- nausea
- vomiting
- diarrhea
- dry skin
- decreased appetite
- rash
- swelling of the face, arms, and legs
- chills
- bleeding
- cough
- shortness of breath

New or worsening high blood pressure (hypertension). Your health care provider should check your blood pressure during treatment with MEKINIST. Call your health care provider right away if you develop high blood pressure, your blood

of you develop high blood pressure, your blood pressure worsens, or you have severe headache, lightheadedness, blurry vision, or dizziness.

Fertility problems. TAFINLAR and MEKINIST, in combination, may cause fertility problems in women. This could affect the ability to become pregnant. Talk to your health care provider if this is a concern for you.

Low sperm counts. TAFINLAR may cause lower sperm counts in men. This could affect the ability to father a child. Talk to your health care provider if this is a concern for you.

Nursing mothers. It is not known if TAFINLAR and/or MEKINIST pass into breast milk. Do not breastfeed during treatment, and for 4 months after your last dose of TAFINLAR and MEKINIST. Talk to your health care provider about the best way to feed your baby during this time.

These are not all the possible side effects of TAFINLAR and MEKINIST. For more information about side effects, ask your health care provider or pharmacist.

Before you take TAFINLAR and MEKINIST in combination, tell your health care provider about all your medical conditions, including if you:

- have had bleeding problems or blood clots
- have stomach problems
- have inflammation of the colon
- have heart problems
- have eye problems
- have lung or breathing problems

- have high blood pressure (hypertension)
- have liver or kidney problems
- have diabetes
- plan to have surgery, dental, or other medical procedures
- have a deficiency of the G6PD enzyme
- are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your health care provider and pharmacist when you get a new medicine.

Please read the Medication Guide for TAFINLAR

Please read the Medication Guide for TAFINLAR and the Patient Information for MEKINIST and discuss any questions you have with your health care provider.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.








Take your medication at least 1 hour before or at least 2 hours after eating.

Capsules and tablet shown are not actual size or likeness



12-hour interval between TAFINLAR doses

Take MEKINIST at the same time each day with either the morning dose or evening dose of TAFINLAR

IMPORTANT SAFETY INFORMATION (continued)

Fever. Fever is common during treatment with TAFINLAR and MEKINIST, but it may also be serious. When taking TAFINLAR and MEKINIST, in combination, fever may happen often or may be severe. In some cases, chills or shaking chills, too much fluid loss (dehydration), low blood pressure, dizziness, or kidney problems may happen with the fever. Call your health care provider right away if you get a fever while taking TAFINLAR or MEKINIST.

Your health care provider may temporarily or permanently stop your treatment or change your dose of MEKINIST with TAFINLAR if you have fevers. Your health care provider will treat you as needed for your fever and any signs and symptoms of infection and should check your kidney function during and after you have had severe fever.

How should I take TAFINLAR?


- Take TAFINLAR exactly as your health care provider tells you. Do not change your dose or stop TAFINLAR unless your health care provider tells you
- Your health care provider may change your dose of TAFINLAR, temporarily stop, or completely stop your treatment with TAFINLAR if you develop certain side effects
- Take TAFINLAR 2 times a day, about 12 hours apart
- Take TAFINLAR at least 1 hour before or 2 hours after a meal
- Do not open, crush, or break TAFINLAR capsules
- If you miss a dose of TAFINLAR, take it as soon as you remember. If it is within 6 hours of your next scheduled dose, just take your next dose at your regular time. Do not make up for the missed dose

How should I take MEKINIST?

- Take MEKINIST exactly as your health care provider tells you to take it. Do not change your dose or stop MEKINIST unless your health care provider tells you
- Your health care provider may change your dose of MEKINIST, temporarily stop, or completely stop your treatment with MEKINIST if you develop certain side effects
- ◆ Take MEKINIST one time a day, about every 24 hours
- ◆ Take MEKINIST at least 1 hour before or 2 hours after a meal
- If you miss a dose, take it as soon as you remember. If it is less than 12 hours before your next scheduled dose, skip the missed dose. Just take the next dose at your regular time

It is important that you understand and follow your health care provider's directions for taking TAFINLAR + MEKINIST. Do not change your dose or stop TAFINLAR or MEKINIST, unless your health care provider tells you to.

Develop a routine for taking your medicine that fits your daily schedule





...and then you can take TAFINLAR again in the evening, at least 2 hours after dinner

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.





Storing TAFINLAR and MEKINIST

IMPORTANT SAFETY INFORMATION (continued)

Serious skin reactions. Skin rash is a common side effect of TAFINLAR and MEKINIST. In some cases, these rashes and other skin reactions can be severe or serious, may need to be treated in a hospital, or lead to death.

- tell your health care provider if you get a skin rash or acne that bothers you or worsens
- tell your health care provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including:
- blisters or peeling of your skin
- mouth sores
- high fever or flu-like symptoms

- o blisters on your lips, or around your mouth or eyes
- enlarged lymph nodes

Storing TAFINLAR

- Store TAFINLAR at room temperature, between 68°F to 77°F (20°C-25°C)
- The bottle of TAFINLAR contains a desiccant packet to help keep your medicine dry. Do not throw away the desiccant packet
- Keep TAFINLAR and the drying agent (desiccant) in the original bottle to protect from moisture

Storing MEKINIST

- Store MEKINIST in the refrigerator between 36°F and 46°F (2°C-8°C)
- Keep MEKINIST dry and away from moisture and light
- The bottle of MEKINIST contains a desiccant packet to help keep your medicine dry. Do not throw away the desiccant packet
- Keep MEKINIST in its original bottle. Do not place tablets in a pill box
- Safely throw away MEKINIST that is out of date or no longer needed



Keep TAFINLAR, MEKINIST, and all medicines out of the reach of children.

IMPORTANT SAFETY INFORMATION (continued)

Increased blood sugar (hyperglycemia). Some people may develop high blood sugar or worsening diabetes during treatment with TAFINLAR and MEKINIST in combination. If you are diabetic, your health care provider should check your blood sugar levels closely during treatment with TAFINLAR and MEKINIST. Your diabetes medicine may need to be changed. Tell your health care provider if you have any of the following symptoms of severe high blood sugar:

- increased thirst
- urinating more often than normal, or urinating an increased amount of urine

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.





Getting the most out of your treatment

IMPORTANT SAFETY INFORMATION (continued)

TAFINLAR may cause healthy red blood cells to break down too early in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This may lead to a type of anemia called hemolytic anemia, where the body does not have enough healthy red blood cells. Tell your health care provider if you have any of the following signs or symptoms:

- yellow skin (jaundice)
- weakness or dizziness
- shortness of breath

Hemophagocytic Lymphohistiocytosis (HLH). TAFINLAR when taken with MEKINIST may increase the risk of a type of overactivity of the immune system (hemophagocytic lymphohistiocytosis) that can cause fever, swollen glands, bruising, or skin rash. If you experience a combination of these symptoms, call your health care provider right away.

Before starting treatment

It is important to keep an open dialogue with your health care provider. **Before you take**TAFINLAR + MEKINIST in combination, tell your health care provider about all your medical conditions, including if you:

- have had bleeding problems or blood clots
- have stomach problems
- have inflammation of the colon
- have heart problems
- have eye problems
- have lung or breathing problems
- have high blood pressure (hypertension)

- have liver or kidney problems
- have diabetes
- plan to have surgery, dental, or other medical procedures
- have a deficiency of the G6PD enzyme
- are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your health care provider and pharmacist when you get a new medicine.

Questions to ask your health care provider

Talking openly with your health care provider is important in making informed decisions about your treatment journey. These suggested questions are a starting point to help you learn more about your cancer care and treatment. You are also encouraged to ask additional questions that are important to you.

- How will we know if the treatment is working?
- What side effects should I expect on treatment?
- Is there anything I can do to help manage side effects?
- What symptoms or side effects should I tell you about right away?

- ◆ Do I need to change what I eat during treatment?
- Are there any limits on what I can do?
- What kind of exercise should I do, and how often?
- Will I need special tests such as imaging scans and blood tests, and how often?

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.





20 Common side effects of TAFINLAR + MEKINIST

How your health care provider may help you manage your fever **21**

Common side effects of TAFINLAR + MEKINIST

As with many medications, you may experience some side effects while taking TAFINLAR + MEKINIST in combination. Below are some common side effects of treatment in people with NSCLC.

- Fever
- Tiredness
- Nausea
- Vomiting

- Diarrhea (call your health care provider if you get severe diarrhea) • Swelling of the face,
- Dry skin
- Decreased appetite
- Rash
 - arms, and leas
- Chills
- Bleedina Cough
- Shortness of breath

Taking TAFINLAR + MEKINIST may cause serious side effects, including:

- Risk of new skin cancers
- Bleeding problems
- Inflammation of the intestines or tears (perforation) of the stomach or intestines
- Blood clots
- Heart problems, including heart failure

- Eye problems
- Lung or breathing problems
- Fever
- Serious skin reactions
- Increased blood sugar (hyperglycemia)

- New or worsening high blood pressure (hypertension)
- Healthy red blood cells to break down too early in people with G6PD deficiency
- Fertility problems
- Low sperm counts

IMPORTANT SAFETY INFORMATION (continued)

TAFINLAR and MEKINIST, in combination, can harm your unborn baby.

Your health care provider will do a test to see if you are pregnant before starting treatment with TAFINLAR and MEKINIST in combination.

Women who are able to become pregnant should use effective birth control (contraception) during treatment with TAFINLAR and MEKINIST in combination, and for 4 months after stopping treatment with TAFINLAR and MFKINIST.

Birth control using hormones (such as birth control pills, injections, or transdermal systems) may not work as well while you are taking TAFINLAR and MEKINIST in combination. You should use another effective method of birth control while taking TAFINLAR and MEKINIST in combination.

Talk to your health care provider about birth control methods that may be right for you during this time.

Tell your health care provider right away if you become pregnant, or think you might be pregnant, during treatment with TAFINLAR and MEKINIST in combination.

Men (including those who have had a vasectomy) with a female partner who is able to become pregnant should use condoms during sexual intercourse during treatment with TAFINLAR and MEKINIST for at least 4 months after your last dose of TAFINLAR and MEKINIST in combination.

How your health care provider may help you manage your fever

Fever is a common side effect of TAFINLAR + MEKINIST combination therapy, but it may also be serious. When taking TAFINLAR + MEKINIST, fever may occur frequently or may be severe. In some cases, chills or shaking chills, too much fluid loss (called "dehydration"), low blood pressure, dizziness, or kidney problems can occur with the fever.

What to do if you think you may have a fever

As soon as you start feeling unusually warm or cold, check your temperature. Call your health care provider right away if you get a fever while taking TAFINLAR + MEKINIST. Your health care provider may recommend that you:



Drink liquids (for example, water, soups, ice pops) to prevent dehydration



Place a cold cloth on your forehead if you feel hot



Get plenty of rest



Use over-the-counter antifever medicines such as acetaminophen or ibuprofen as needed according to your health care provider's instructions

Your health care provider may temporarily or permanently stop your treatment or change your dose of MEKINIST with TAFINLAR if you have fevers. Your health care provider will treat you as needed for your fever and any signs and symptoms of infection, and should check your kidney function during and after you have had severe fever.

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of TAFINLAR, in combination with MEKINIST, when used in people with NSCLC, include:

fever tiredness

• diarrhea dry skin

- swelling of the face, arms, and leas
- chills
- decreased appetite nausea vomiting • rash
- bleeding
- cough
 - shortness of breath

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.

Please see accompanying full Prescribing Information for TAFINLAR, including Medication Guide, and <u>full Prescribing Information for MEKINIST</u>, including Patient Information.







Your Wallet Card

Use this wallet card to communicate with health care providers and carry it with you in case of an emergency.

If you visit the emergency room, or doctors not on your health care team, please hand it to them so they know you are being, treated with TAFINLAR + MEKINIST. Always remember to tell your health care provider about any side effect that bothers you or does not go away, such as fever.

Simply print this page, cut out the card below, and carry it in your wallet.

If you visit the emergency room, or doctors outside of your care team, show this card so they know you're being treated with TAFINLAR + MEKINIST.



Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 © 2024 Novartis 5/24 426665



Your Wallet Card

Use this wallet card to communicate with health care providers and carry it with you in case of an emergency.

If you visit the emergency room, or doctors not on your health care team, please hand it to them so they know you are being treated with TAFINLAR + MEKINIST.

Always remember to tell your health care provider about any side effect that bothers you or does not go away, such as fever.

Simply print this page, cut out the card below, and carry it in your wallet.

/ly Name:

I am being treated with TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets combination therapy.


My Doctor's Name:

Phone

Please visit www.us.tafinlarmekinist.com for full Prescribing Information for TAFINLAR, including Medication Guide, and full Prescribing Information for MEXINIST including Partials Information







• How long do I take TAFINLAR and MEKINIST?

Keep taking TAFINLAR + MEKINIST for as long as your health care provider tells you. Tell your health care provider if you have any side effect that bothers you or that does not go away.

• What if I miss a dose?

If you miss a dose of TAFINLAR or MEKINIST, take it as soon as you remember. But if you miss TAFINLAR, and it is within 6 hours of your next scheduled dose, or if you miss MEKINIST, and it is within 12 hours of your next scheduled dose, just take your next dose at the regular time. Do not make up for the missed dose.

Q. What can I do about side effects?

Tell your health care provider if you have any side effect that bothers you or that does not go away. Your health care provider may change, temporarily interrupt, or decrease your dose of TAFINLAR and/or MEKINIST during your treatment to help manage side effects. Depending on side effect and severity, your health care provider may need to discontinue your treatment. If you have any questions about your treatment, talk to your health care provider. Please see pages 10 to 13 for the Summary of Important Information for TAFINLAR + MEKINIST.

Q. Do I need to take every dose?

It is important to take TAFINLAR + MEKINIST exactly as your health care provider tells you. Do not change your dose or stop taking TAFINLAR or MEKINIST unless your health care provider tells you.

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.





How can I learn more about NSCLC?

IMPORTANT SAFETY INFORMATION (continued)

These are not all the possible side effects of TAFINLAR and MEKINIST. For more information about side effects, ask your health care provider or pharmacist.

Before you take TAFINLAR and MEKINIST in combination, tell your health care provider about all your medical conditions, including if you:

- have had bleeding problems or blood clots
- have stomach problems
- have inflammation of the colon
- have heart problems
- have eye problems

- have lung or breathing problems
- have high blood pressure (hypertension)
- have liver or kidney problems
- have diabetes

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.

Please <u>click here</u> for full Prescribing Information for TAFINLAR and <u>click here</u> for full Prescribing Information for MEKINIST.

Many organizations offer support and information for people with lung cancer. Some of the websites listed here provide information about health insurance issues and support programs available for people with non-small cell lung cancer. Several of the websites offer forums where you can connect with other patients and caregivers.

LUNGevity Foundation (www.lungevity.org)

The largest national lung cancer-focused nonprofit organization. Provides patients with lung cancer research, education, and support.

GO₂ Foundation for Lung Cancer (www.go2.org)

A nonprofit organization founded by patients to help empower and educate other patients through all stages of diagnosis, treatment, and care.

Lung Cancer Research Foundation (www.lungcancerresearchfoundation.org)

An organization in partnership with lung cancer survivors, advocates, researchers, health care professionals, and industry leaders. The website provides information about lung cancer types, tips on how to deal with diagnoses, and information about research-funding walks.

CancerCare (www.cancercare.org/diagnosis/lung_cancer)

A patient support-based website offering face-to-face, online, and telephone contact with oncology social workers, while also providing inspirational stories from patients.

Cancer Support Community (www.cancersupportcommunity.org/non-small-cell-lung-cancer)

A support-oriented site focused on improving a patient's mindset and providing advice on how to live with cancer.

The organizations and websites listed above are external to Novartis. Novartis does not have control over the information provided on these websites and, therefore, cannot guarantee their accuracy and completeness. Any information you receive from these sites should not replace the medical advice from your health care provider.

Support designed for patients and caregivers

- Insurance and Medicare education to help you understand the insurance process
- Financial assistance for eligible patients*
- Information about independent organizations that can assist with your day-to-day needs beyond medical care[†]
- Patient Support Counselors who are able to provide information in more than 160 languages

*Novartis Pharmaceuticals Corporation does not guarantee success in obtaining reimbursement or financial assistance. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved.

 † All organizations are not-for-profit and/or government agencies, and are independent of Novartis Pharmaceuticals Corporation.

To learn more about what's available, call 1-800-282-7630 or visit Patient.NovartisOncology.com.

Novartis Oncology Universal Co-pay Program

U NOVARTIS



To find out if you are eligible, call 1-877-577-7756, or visit Copay.NovartisOncology.com

You may be eligible for immediate co-pay savings on your next prescription of TAFINLAR + MEKINIST.

- Eligible patients with private insurance may pay \$0 per month (\$0 per month for a 30-day supply of TAFINLAR and \$0 for a 30-day supply of MEKINIST). Co-pay of \$0 is only for TAFINLAR and MEKINIST combination therapy
- Novartis will pay the remaining co-pay, up to \$15,000 per calendar year, per product*

To find out if you are eligible for the Universal Co-pay Program, call **1-877-577-7756** or visit **CoPay.NovartisOncology.com**.

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit Copay.NovartisOncology.com or call 1-877-577-7756.

Patient Assistance Now Oncology



Our Patient Assistance Now Oncology (PANO) program was created to assist you with accessing your Novartis medicine(s)—from insurance verification to financial assistance—all through a knowledgeable and supportive call center.

To learn more, call **1-800-282-7630** or visit **Patient.NovartisOncology.com**.

Free Trial and Access Program

With the Free Trial and Access Program, you can receive a free supply of TAFINLAR and MEKINIST for a US Food and Drug Administration—approved indication. The supply can be shipped directly to your home or another convenient location so you can start treatment immediately. Program rules may vary by product.

Ask your health care professional to help you apply for the PANO Free Trial and Access Program.





Visit www.us.tafinlarmekinist.com for more information and patient support.

IMPORTANT SAFETY INFORMATION (continued)

- plan to have surgery, dental, or other medical procedures
- have a deficiency of the G6PD enzyme
- are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your health care provider and pharmacist when you get a new medicine.

Please read the Medication Guide for TAFINLAR and the Patient Information for MEKINIST and discuss any questions you have with your health care provider.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.





